|
|
|
| At the Festival of Opportunity, we’re asking bold questions. Matthew Griffin, Futurist in Chief at the 311 Institute, opens with a look at how AI, IoT, and synthetic data are reshaping trials. Our largest-ever Regulatory Townhall welcomes regulators from six countries to explore global data governance. We close with Dr. Sara Brenner, Principal Deputy Commissioner at the US FDA, reflecting on COVID-19-era innovation and its lasting impact. Explore the #SCDM25 program. |
|
|
|
|
Life sciences companies can look to the automotive industry for ideas about collaborating with patients to co-create new products, write Noël Theodosiou and Patrick O. Gee. |
|
|
|
|
|
| Key Criteria For Choosing The Right Phase 1 CRO | Phase 1 clinical trials are a pivotal step in developing new therapies. These early-stage studies are crucial for assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of new drugs. |
|
|
|
|
| A Holistic Approach To Process Scale-Up | See a concept designed to optimize both upstream and downstream processes. Find impressive scale-up results achieved from bench-top bioreactor systems to the 200L mammalian single-use stirred tank reactor. |
|
|
|
